T1	Participants 45 100	patients with non-ST elevation acute coronary syndromes
T2	Participants 984 1064	At 6 months, 6.2% of patients died, 12.1% had MI, and 15.7% suffered death or MI
T3	Participants 343 772	evaluated 26,466 NSTE ACS patients from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb), Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON) A and B trials to ascertain the timing of adverse events.
